Compare PRME & FSTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRME | FSTR |
|---|---|---|
| Founded | 2019 | 1902 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.0M | 442.3M |
| IPO Year | 2022 | 1995 |
| Metric | PRME | FSTR |
|---|---|---|
| Price | $4.23 | $41.77 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | $7.03 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 5.5M | 32.8K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | $4,632,000.00 | ★ $540,009,000.00 |
| Revenue This Year | $18.58 | $6.53 |
| Revenue Next Year | $23.34 | $4.30 |
| P/E Ratio | ★ N/A | $39.63 |
| Revenue Growth | ★ 55.28 | 1.74 |
| 52 Week Low | $2.67 | $25.66 |
| 52 Week High | $5.91 | $45.81 |
| Indicator | PRME | FSTR |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 63.80 |
| Support Level | $2.94 | $40.01 |
| Resistance Level | $4.80 | $43.03 |
| Average True Range (ATR) | 0.53 | 1.47 |
| MACD | -0.08 | 0.52 |
| Stochastic Oscillator | 22.25 | 78.80 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.